Rasagiline Mesylate
NDC Package 60505-3608-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Rasagiline Mesylate is rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. Marketed by Apotex Corp, this product is identified by NDC 60505-3608 and is authorized under FDA application ANDA201950.

Identification & Billing

NDC Package Code
60505-3608-3
Package Description
30 TABLET in 1 BOTTLE
Product Code
60505-3608
11-Digit Billing Format
60505360803

Clinical Specifications

Proprietary Name
Rasagiline Mesylate
Dosage Form
-
Usage Information
Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness). Rasagiline belongs to a class of drugs known as MAO inhibitors. It works by increasing the levels of certain natural substances in the brain (such as dopamine, norepinephrine, serotonin). Parkinson's disease is thought to be caused by too little dopamine in the brain.

Regulatory & Marketing

Labeler Name
Apotex Corp
FDA Application #
ANDA201950
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-24-2017
End Marketing Date
11-29-2018
Listing Expiration
11-29-2018
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 60505-3608-3 identifies a specific commercial package of 30 tablet in 1 bottle of Rasagiline Mesylate, labeled by Apotex Corp. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Apotex Corp on April 24, 2017. The current certification is valid through November 29, 2018.

What are the primary indications for this medication?

Rasagiline is used alone or with other medications (such as levodopa/carbidopa) to treat symptoms of Parkinson's disease. It can help improve symptoms such as shakiness, stiffness, and difficulty moving. It can also help reduce the amount of "off" time (periods of slow movement or stiffness). Rasagiline belongs to a class of drugs known as MAO inhibitors. It works by increasing the levels of certain natural substances in the brain (such as dopamine, norepinephrine, serotonin). Parkinson's disease is thought to be caused by too little dopamine in the brain.

How is this Apotex Corp product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 60505360803. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
60505-3608-3
11-Digit CMS (5-4-2)
60505-3608-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.